Griffin Securities Has Announced Investment Opinion on Cancer Targeting Stem Cells

(EMAILWIRE.COM, November 03, 2009 ) November 3, 2009, New York, NY – Keros Capital announces that Griffin Securities (“Griffin”), a research-driven investment banking firm, has released an industry report on the subject of targeting cancer stem cells (CSCs). The stem cell hypothesis offers a rational approach to preventing, diagnosing, and treating malignant growth. Covered in the report are five classes of drugs nearing the Phase II clinical trial that provides human proof-of concept data, a crucial stage of development: Notch signaling, P13k/akt pathway, immunotherapeutics, molecular chaperons, and hedgehog signaling. 

Companies highlighted in the write up include: Bristol Myers Squibb Co. (Public), Calistoga Pharmaceuticals (private), Champions Biotechnology Inc. (Public, OTC:CSBR), Curis, Inc. (Public), Exelixis, Inc., Genentech (private), ImmunoCellular Therapeutics, Ltd. (Public), Infinity Pharmaceuticals Inc. (Public), Keryx Biopharmaceuticals (Public, MabCure Inc (Public, OTC:MBCI), Merck & Co., Inc. (Public), Myriad Pharmaceuticals, Inc. (Public), Novartis AG (ADR) (Public), OncoMed Pharmaceuticals (private), Oncothyreon Inc. (Public), Pfizer Inc. (Public), Rexahn Pharmaceuticals, Inc. (Public), Roche Holding Ltd. (ADR) (Public), Synta Pharmaceuticals Corp. (Public), and Trojantec (Private). 

The report can be downloaded by clicking on the link below: http://www.griffinsecurities.com/pdf/Industry_Reports/Griffin_Industry_Report_-_Targeting_Cancer_Stem_Cells_14Sep09.pdf 

MabCure Inc. (OTCBB: MBCI), a biotech company that has developed a series of highly specific monoclonal antibodies (Mabs) to combat various types of cancers, is also highlighted in the October issue of GEN (Genetic Engineering & Biotechnology News). The article, written by Keith A. Markey, titled "Firms Seek to Prove Cancer Stem Cell Hypothesis," describes MabCure as a company involved in developing immunotherapy against molecules on cancer stem cell surfaces that differ in quantity or quality from those on normal cells. 

About Griffin Securities 

Griffin Securities is a research-driven investment banking firm providing corporate finance, merger & acquisitions, brokerage, and investment opportunities for institutional, corporate, and private clients. The firm is a member of the Financial Industry Regulatory Authority (FINRA) (www.finra.org) and the Securities Investor Protection Corporation (SIPC) (www.sipc.org). Griffin Securities is headquartered in New York City and has no other domestic or international affiliates or subsidiaries. 

About MabCure Inc.

MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which will be developed as diagnostic tools, imaging agents, and drugs to treat lethal cancers. MabCure initial goal is to develop its novel MAbs as diagnostic tools for the detection of Ovarian and Prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit the Company's website www.mabcure.com.

Disclosure:  All material herein was prepared by Keros Capital Inc. (Keros) based upon information believed to be reliable. The information contained herein is not guaranteed by Keros to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Keros is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.keroscapital.com or mentioned herein.  Keros has been compensated seven thousand five hundred dollars for this advertising effort.  Keros may receive additional compensation for future advertisements. Keros affiliates, officers, directors and employees may own shares and may buy and sell additional shares of the company mentioned herein and may profit in the event those shares rise in value.  Keros will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.  Copyright 2007 by Keros Capital.  All rights reserved.  This publication or part thereof may not be duplicated or reprinted without the written permission of the Publisher. Facsimile including photocopy(s) is strictly forbidden, except for facsimile correspondence between Keros Capital.  If this publication contravenes any securities laws and/or regulations, the securities regulations of the country will prevail.  In this event, this publication must be discarded immediately.
  

MabCure Inc.
         Jim Mav
         908-464-1747
         jimmav@keroscapital.com